Everything below concerns IGF-1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-24. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
A glycome is the entire complement or complete set of all sugars, whether free or chemically bound in more complex molecules, of an organism. An alternative definition is the entirety of carbohydrates in a cell. The glycome may in fact be one of the most complex entities in nature. "Glycomics, analogous to genomics and proteomics, is the systematic study of all glycan structures of a given cell type or organism" and is a subset of glycobiology. "Carbohydrate", "glycan", "saccharide", and "sugar" are generic terms used interchangeably in this context and includes monosaccharides, oligosaccharides, polysaccharides, and derivatives of these compounds. Carbohydrates consist of "hydrated carbon", i.e. [CH2O]n. Monosaccharides are a carbohydrate that cannot be hydrolyzed into a simpler carbohydrate and are the building blocks of oligosaccharides and polysaccharides. Oligosaccharides are linear or branched chains of monosaccharides attached to one another via glycosidic linkages. The number of monosaccharide units can vary. Polysaccharides are glycans composed of repeating monosaccharides, generally greater than ten monosaccharide units in length. The glycome exceeds the complexity of the proteome as a result of the even greater diversity of the glycome's constituent carbohydrates and is further complicated by the sheer multiplicity of possibilities in the combination and interaction of the carbohydrates with each other and with proteins. "The spectrum of all glycan structures — the glycome — is immense.
== Antivenom == The antivenom was developed by a team headed by Struan Sutherland at the Commonwealth Serum Laboratories (CSL) in Melbourne. Since the antivenom became available in 1981, there have been no recorded fatalities from Sydney funnel-web spider bites. In September 2012, it was reported that stocks of antivenom were running low, and members of the public were asked to catch the spiders so that they could be milked for their venom. The venom is taken from the spiders by delicately stroking their fangs and collecting the tiny droplets of the deadly venom. The venom is needed to produce the antivenom. One dose of antivenom requires around 70 milkings from a spider. Funnel web spider antivenom is prepared from the plasma of rabbits immunized with the venom of the male funnel web spider (Atrax robustus). Each vial of the product contains 125 units of antivenom which has been standardized to neutralize 1.25 mg of funnel web spider venom. The product also contains glycine and other rabbit plasma proteins. Funnel web spider antivenom is a purified immunoglobulin (mainly immunoglobulin G), derived from rabbit plasma, which contains specific antibodies against the toxic substances in the venom of the funnel web spider, Atrax robustus. There is evidence to show that the antivenom is effective in the treatment of patients bitten by some other funnel web spiders of the genus Hadronyche (formerly Atrax).
== Non-inertial frame of reference == The rotating frame of reference introduces some interesting pseudo-forces into the equations through the material derivative term. Consider a stationary inertial frame of reference
=== Wappani === Wappani (わっぱ煮), a miso-soup-based dish, is unique to Awashima island off the coast of Niigata, Japan. A cedar flask ("wappa") is filled with miso soup, fish and vegetables. It is then heated by dropping in hot rocks, which quickly brings it to a simmer. Hot rocks retain their heat for hours after being taken from the fire, so a hot meal can be prepared without the use of fire.
Sources: en.wikipedia.org
One of the first adoptions of the trope is Rachel Pollack's Tree House (1984). The titular megaflora in Larry Niven's 1984 novel The Integral Trees exist within an orbiting gaseous torus full of life adapted to free-fall. The concept is discussed in Carl Sagan and Ann Druyan's 1985 non-fiction book Comet, and several paintings of Dyson trees around Saturn and in interstellar space are provided in the book by Jon Lomberg. In Michael Swanwick's 1987 transhumanist novel Vacuum Flowers, "dysonsworlders" have established tree settlements in the Oort Cloud. Under the name of "Space Poplars", Dyson trees are described in Donald Moffitt's two science fiction novels, The Genesis Quest and Second Genesis. Here they are used as both habitats and spacecraft, propelled by reflective outer leaves used as organic solar sails. Dan Simmons, in Endymion (1996) and the Rise of Endymion (1997) – both part of his Hyperion Cantos – refers to Dyson trees, and in the latter novel to a huge tree system that surrounds an entire star (reminiscent of a Dyson sphere). In Stephen Baxter's Manifold: Space (2001), Baxter's protagonist Reid Malenfant at one point finds himself inside a Dyson tree. In the Orion's Arm shared universe (established 2000), Dyson trees and Dyson tree "forests" are called orwoods; these have been established in a number of star systems throughout terragen space. The word "Orwood" in this context was originally coined by Anders Sandberg. The Transhuman Space roleplaying game includes the beginning of a Dyson tree endeavour on Yggdrasil Station.
=== Regional chains === MEGA MART, Owner by Nongshim JangbogoFoodMart, JangbogoFoodMart is a regional supermarket chain in Korea, focusing on Gyeongsang Province. Owner by JangbogoFoodMart Co, LTD. TopMart, TopMart is a regional supermarket chain in Korea, focusing on Gyeongsang Province. Owner by SEOWON DISTRIBUTION Co., Ltd. TRIAL, TRIAL is Japan Supermarket Chain Group. South Korea Store Owner by TRIAL Korea Co., Ltd. IGA Segyero Mart
=== Mikel Brady === Mikel Edward Brady II (born March 11, 1989), the ringleader of the prison escape and murders, originally came from Randolph, Vermont, where he was born and raised. Brady reportedly had an unhappy childhood marred by abuse. He was born to a teenage mother and raised by a physically abusive father. From an early age, Brady suffered from developmental issues and was later diagnosed with bipolar disorder and post-traumatic stress disorder (PTSD). Despite these diagnoses, Brady's father was reportedly against him taking prescribed medications, preventing him from receiving proper treatment during his formative years. Brady's descent into criminal behavior began during his teenage years. He became involved in a drug and burglary ring responsible for numerous break-ins in the Randolph area. In 2008, he was arrested for stealing 209 sticks of dynamite from a quarry in Bethel, Vermont. The following year, in 2009, he was charged in connection with a violent home invasion in South Royalton that left the victim with a severe brain injury. Attempting to evade the law, Brady fled to Mexico, but he was eventually captured, extradited, and imprisoned in Vermont. After serving the minimum sentence and demonstrating good behavior behind bars, Brady was released in 2012. For a brief period, it seemed as though he was turning his life around. He found employment at a butcher shop in Randolph, joined a local softball league, and began taking his medications consistently. During this time, his girlfriend became pregnant, and the couple welcomed a son.
Patients with no history of red cell antibodies may qualify for computer-assisted crossmatch, which does not involve combining patient serum with donor cells. If an antibody is suspected, potential donor units must first be screened for the corresponding antigen by phenotyping them. Antigen negative units are then tested against the patient plasma using an antiglobulin/indirect crossmatch technique at 37 degrees Celsius to enhance reactivity and make the test easier to read. In urgent cases where crossmatching cannot be completed, and the risk of dropping hemoglobin outweighs the risk of transfusing uncrossmatched blood, O-negative blood is used, followed by crossmatch as soon as possible. O-negative is also used for children and women of childbearing age. It is preferable for the laboratory to obtain a pre-transfusion sample in these cases so a type and screen can be performed to determine the actual blood group of the patient and to check for alloantibodies.
centromeric index The proportion of the total length of a chromosome encompassed by its short arm, typically expressed as a percentage; e.g. a chromosome with a centromeric index of 15 is acrocentric, with a short arm comprising only 15% of its overall length.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.